NeoGenomics, Inc. (NASDAQ:NEO) Shares Sold by Truist Financial Corp

Truist Financial Corp trimmed its holdings in NeoGenomics, Inc. (NASDAQ:NEO) by 5.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 30,037 shares of the medical research company’s stock after selling 1,757 shares during the quarter. Truist Financial Corp’s holdings in NeoGenomics were worth $495,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Versant Capital Management Inc raised its holdings in NeoGenomics by 174.9% during the 4th quarter. Versant Capital Management Inc now owns 1,795 shares of the medical research company’s stock worth $30,000 after buying an additional 1,142 shares during the period. Quarry LP acquired a new stake in NeoGenomics during the 3rd quarter worth about $40,000. KBC Group NV increased its holdings in shares of NeoGenomics by 33.1% in the 3rd quarter. KBC Group NV now owns 4,530 shares of the medical research company’s stock valued at $67,000 after purchasing an additional 1,127 shares during the period. Blue Trust Inc. increased its holdings in shares of NeoGenomics by 33.2% in the 4th quarter. Blue Trust Inc. now owns 4,421 shares of the medical research company’s stock valued at $73,000 after purchasing an additional 1,103 shares during the period. Finally, FMR LLC increased its holdings in shares of NeoGenomics by 7.6% in the 3rd quarter. FMR LLC now owns 13,255 shares of the medical research company’s stock valued at $196,000 after purchasing an additional 931 shares during the period. 98.50% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on NEO. Needham & Company LLC dropped their target price on NeoGenomics from $19.00 to $18.00 and set a “buy” rating on the stock in a report on Wednesday, February 19th. Bank of America dropped their target price on NeoGenomics from $19.00 to $16.00 and set a “neutral” rating on the stock in a report on Wednesday, February 19th. Piper Sandler dropped their target price on NeoGenomics from $21.00 to $18.00 and set an “overweight” rating on the stock in a report on Wednesday, February 26th. Benchmark downgraded NeoGenomics from a “buy” rating to a “hold” rating in a report on Monday, January 13th. Finally, The Goldman Sachs Group dropped their target price on NeoGenomics from $20.00 to $18.00 and set a “buy” rating on the stock in a report on Tuesday, January 28th. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $19.60.

NeoGenomics Trading Down 4.1 %

NASDAQ:NEO opened at $9.58 on Tuesday. The stock’s 50 day moving average price is $14.35 and its 200 day moving average price is $15.19. NeoGenomics, Inc. has a 52 week low of $9.56 and a 52 week high of $19.11. The company has a market capitalization of $1.23 billion, a P/E ratio of -15.45 and a beta of 1.23. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.91 and a current ratio of 1.98.

NeoGenomics (NASDAQ:NEO) last announced its earnings results on Tuesday, February 18th. The medical research company reported ($0.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.05). The company had revenue of $172.00 million for the quarter, compared to the consensus estimate of $173.40 million. NeoGenomics had a negative return on equity of 2.10% and a negative net margin of 11.92%. On average, research analysts forecast that NeoGenomics, Inc. will post -0.2 EPS for the current fiscal year.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.